Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-10

Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of erenumab (AMG 334) for migraine prevention has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • erenumab (erenumab)

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2018-07-10